Limitation of activity in an acute model of arthritis: Effect of drug treatment

被引:5
作者
Bliven, ML [1 ]
Eskra, JD [1 ]
Otterness, IG [1 ]
机构
[1] Pfizer Inc, Div Cent Res, Dept Canc Immunol & Infect Dis, Groton, CT 06340 USA
关键词
arthritis; hamster; quality-of-life; outcome measures; tenidap;
D O I
10.1007/s000110050231
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective and Design: The limitation of activity and its modification by therapy in an experimental arthritis was studied. Subjects: Female hamsters in groups of six per treatment were used. Treatment: An acute arthritis was induced by intraarticular injection of 0.1 mu g lipopolysaccharide (LPS) in hamsters with free access to running wheels. Tenidap at 100 mg%, and piroxicam and indomethacin at 30 mg% were administered in the hamster's normal diet. Methods: Activity was monitored and analysed by computer. Plasma blood levels of drugs were determined by high pressure liquid chromatographic (HPLC) analysis. Results: Hamsters normally run 10-15 km/day. That distance was reduced to less than 2 km/day after arthritis induction. Speed of movement, essentially the equivalent of walking time, was reduced 40% by the arthritis. However, the time spent in movement (activity time) was more severely affected by arthritic disease. Therapy gave a modest 1.3-fold increase in speed of movement, but a highly significant 2-fold increase in activity time. Conclusions: The effects of arthritis on activity in this animal model suggest that time spent in movement (activity time) should be considered as an outcome measure in clinical studies. These observations may also help explain why the modest disease improvements obtained with cyclooxygenase inhibition are valued. From a patient perspective, a doubling of activity time is a highly significant improvement in quality-of-life.
引用
收藏
页码:491 / 495
页数:5
相关论文
共 19 条
  • [1] TENIDAP IN RHEUMATOID-ARTHRITIS - A 24-WEEK DOUBLE-BLIND COMPARISON WITH HYDROXYCHLOROQUINE-PLUS-PIROXICAM, AND PIROXICAM ALONE
    BLACKBURN, WD
    PRUPAS, HM
    SILVERFIELD, JC
    POILEY, JE
    CALDWELL, JR
    COLLINS, RL
    MILLER, MJ
    SIKES, DH
    KAPLAN, H
    FLEISCHMANN, R
    SCOVILLE, CD
    RUTSTEIN, JE
    HURD, ER
    LOUIE, JS
    BANKHURST, AD
    WEAVER, AL
    SEBBA, AI
    APPELROUTH, DJ
    HUDSON, NP
    GORDON, GV
    GORDON, RD
    LUDIVICO, CL
    AUSTIN, MC
    SANDERS, KM
    SCHUETTE, PT
    MOIDEL, RA
    KRASKA, AR
    TING, NT
    SHANAHAN, WR
    LOOSE, LD
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (10): : 1447 - 1456
  • [2] CALDWELL JR, 1995, BR J CLIN PHARM, V39, P3
  • [3] THE DETERMINANTS OF WALKING VELOCITY IN THE ELDERLY
    CHANG, RW
    DUNLOP, D
    GIBBS, J
    HUGHES, S
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (03): : 343 - 350
  • [4] SELF-ADMINISTRATION OF THE ANALGESIC SUPROFEN IN ARTHRITIC RATS - EVIDENCE OF MYCOBACTERIUM-BUTYRICUM-INDUCED ARTHRITIS AS AN EXPERIMENTAL-MODEL OF CHRONIC PAIN
    COLPAERT, FC
    DEWITTE, P
    MAROLI, AN
    AWOUTERS, F
    NIEMEGEERS, CJE
    JANSSEN, PAJ
    [J]. LIFE SCIENCES, 1980, 27 (11) : 921 - 928
  • [5] FURTHER EVIDENCE VALIDATING ADJUVANT ARTHRITIS AS AN EXPERIMENTAL-MODEL OF CHRONIC PAIN IN THE RAT
    COLPAERT, FC
    MEERT, T
    DEWITTE, P
    SCHMITT, P
    [J]. LIFE SCIENCES, 1982, 31 (01) : 67 - 75
  • [6] GEGOUT P, 1995, LIFE SCI, V56, P389
  • [7] Gegout P, 1994, LIFE SCI, V55, P321
  • [8] GENANT HK, 1995, RHEUMATOL EUR, V24, P224
  • [9] PIROXICAM PHARMACOKINETICS IN MAN - ASPIRIN AND ANTACID INTERACTION STUDIES
    HOBBS, DC
    TWOMEY, TM
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 19 (5-6) : 270 - 281
  • [10] LEWIS AJ, 1987, NONSTEROIDAL ANTIINF